Citius Pharmaceuticals

Citius has historically relied on public equity offerings, registered direct placements, and warrant exercises to finance its pipeline. The firm reported $19.1 million in cash and cash equivalents as of March 2025 and has carried no long-term debt. Because it licenses late-stage, derisked molecules rather than conducting early-stage drug discovery, its monthly cash burn remains substantially lower than a comparably staged biotech advancing from preclinical work.

Lymphir is a purified reformulation of denileukin diftitox, an IL-2 receptor-targeted fusion protein previously marketed as ONTAK for cutaneous T-cell lymphoma until it was voluntarily withdrawn in 2014 due to manufacturing impurities. Citius reformulated the drug to improve purity and secured FDA priority review in August 2024. The critical binary milestone is FDA approval; the target action date was set for early 2025, and approval would represent the firm's first commercially marketed product (per the firm, August 2024).

Executive Chairman Leonard Mazur, who founded the company in 2007, retains outsized influence over strategic direction. Myron Holubiak has served as President and previously held the CEO title. The Board of Directors, which includes several independent members, oversees major corporate transactions such as the November 2024 subsidiary restructuring that created Citius Oncology as a standalone public company.

Mino-Lok is an antibiotic lock solution combining minocycline, EDTA, and ethanol designed to salvage infected central venous catheters in patients with limited vascular access. A Phase 3 trial completed in 2022 but failed to meet its primary endpoint of reducing catheter-related bloodstream infections; the company has stated it will hold the asset and evaluate next steps while focusing resources on Lymphir (per SEC filings, 2024).

On November 22, 2024, Citius distributed shares of its wholly owned subsidiary Citius Oncology to existing Citius Pharma shareholders, creating two independent Nasdaq-listed entities. Citius Oncology (CTOR) holds Lymphir and its associated regulatory pathway, while the legacy parent retains Mino-Lok, Halo-Lido, and future in-licensing activity. The restructuring isolates Lymphir's regulatory binary from the parent's remaining pipeline, theoretically reducing crossover risk for shareholders and giving each asset its own capital-raising vehicle.

No. Citius Pharmaceuticals is a publicly traded C-corporation listed on Nasdaq under the ticker CTXR. It is not a family office, does not manage third-party capital under an investment-advisory structure, and is primarily capitalized through institutional and retail equity investors in the public markets rather than through limited-partner commitments.

Leonard Mazur previously co-founded Triax Pharmaceuticals, a specialty dermatology company acquired by Precision Dermatology, and served as COO of Genesis Pharmaceutical. His career has centered on the commercialization of niche, high-acuity products rather than novel drug discovery. That operational experience informs Citius's strategy of acquiring existing molecules with established safety profiles and repurposing them for underserved critical-care indications, a model that requires lean clinical execution rather than large-scale R&D infrastructure.